Instil Bio, Inc.
Instil Bio, Inc.
Your view on TIL
Overview
What the company does, where it operates, and who runs it.
About Instil Bio, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Bronson Crouch
- Headquarters
- 3963 Maple Avenue, Dallas, TX, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Bronson Crouch
- Headquarters
- 3963 Maple Avenue, Dallas, TX, US
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL).
Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others.
The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Instil Bio, Inc., and the rating behind it. TIL last traded at $7.38; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Instil Bio, Inc.. Starting points for Instil Bio, Inc.: EPS -$4.46, beta 1.92 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Instil Bio, Inc.. Instil Bio, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Instil Bio, Inc.. Trailing twelve-month EPS for Instil Bio, Inc. stands at -$4.46. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Instil Bio, Inc.. Instil Bio, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Instil Bio, Inc. valued side by side against its closest peers. Instil Bio, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Instil Bio, Inc., and how their positions are changing. At a $50.1M market value, institutional positions materially move Instil Bio, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Instil Bio, Inc. executives and directors. Shares of Instil Bio, Inc. have traded between $10.80 and $42.79 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Instil Bio, Inc.. Instil Bio, Inc. is a $50.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Instil Bio, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Instil Bio, Inc.. Coverage tracks Instil Bio, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.